Jacobs Levy Equity Management, Inc Protagonist Therapeutics, Inc Transaction History

Jacobs Levy Equity Management, Inc

$23.9 Billion
Q1 2025

A detailed history of Jacobs Levy Equity Management, Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 128,654 shares of PTGX stock, worth $6.84 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

128,654

Previous 128,654 -0.0%

Holding current value

$6.84 Million

Previous $4.97 Million 25.27%

% of portfolio

0.03%

Previous 0.02%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $12,038 - $16,896	-357 Reduced 0.28%	128,654 $5.78 Million
Q3 2023 Nov 16, 2023	SELL	$16.68 - $23.66 $291,499 - $413,482	-17,476 Reduced 11.93%	129,011 $2.15 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $1.34 Million - $2.19 Million	-74,504 Reduced 33.71%	146,487 $4.05 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $680,476 - $1.6 Million	-63,124 Reduced 22.22%	220,991 $5.08 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $219,144 - $332,586	29,775 Added 11.71%	284,115 $3.1 Million
Q3 2022 Nov 15, 2022	BUY	$7.86 - $11.71 $2 Million - $2.98 Million	254,340 New	254,340 $2.14 Million
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $1.04 Million - $1.53 Million	-68,279 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$6.19 - $18.84 $25,242 - $76,829	-4,078 Reduced 5.64%	68,279 $1.21 Million
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $105,159 - $179,550	-19,474 Reduced 21.21%	72,357 $511,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $365,918 - $1.05 Million	78,021 Added 564.96%	91,831 $647,000
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $129,952 - $228,693	13,810 New	13,810 $166,000
Q2 2019 Aug 13, 2019	SELL	$8.98 - $12.96 $194,866 - $281,232	-21,700 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$6.5 - $13.77 $43,550 - $92,259	-6,700 Reduced 23.59%	21,700 $273,000
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $11,970 - $19,836	1,900 Added 7.17%	28,400 $191,000
Q3 2018 Nov 14, 2018	BUY	$6.82 - $11.26 $180,730 - $298,390	26,500 New	26,500 $273,000

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

61.3M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.61B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Protagonist Therapeutics, Inc Transaction History